Ribociclib + letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) and central nervous system metastases: Subgroup analysis of the phase IIIb CompLEEment-1 trial

Paul Cottu

San Antonio Breast Cancer Symposium 2020

The presentation that you are looking for is no longer available on this site. Please contact Novartis Oncology Medical Information at 1-844-ONC-INFO (1-844-662-4636).